Autoimmune Encephalitis with Neuropsychiatric Manifestations Secondary to Anti-N
Methyl-D-Aspartate Receptor Antibodies: A Comprehensive Case Analysis and Literature
Review
More details
Hide details
1
Ar-Razi Psychiatric University Hospital, Salé, Morocco
Submission date: 2025-09-28
Acceptance date: 2025-11-02
Online publication date: 2026-01-01
Publication date: 2026-01-01
Corresponding author
Imane Katir
Ar-Razi Psychiatric University Hospital, Salé, Morocco
Arch Psych Psych 2025;27(4):78-84
KEYWORDS
TOPICS
ABSTRACT
Background: Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis represents a
paradigmatic form of autoimmune encephalitis characterized by a constellation of
neuropsychiatric symptoms including psychosis, seizures, cognitive dysfunction, and
movement disorders. This condition poses significant diagnostic challenges due to its
multifaceted clinical presentation that often mimics primary psychiatric disorders.
Objective: To examine the complex diagnostic and therapeutic considerations in a patient
presenting with acute-onset psychosis and seizures secondary to anti-NMDAR encephalitis,
emphasizing the critical importance of early recognition and multidisciplinary management.
Case Summary: We present a 43-year-old postpartum female who developed severe
neuropsychiatric symptoms including acute psychosis, seizures, and cognitive impairment.
Initial psychiatric evaluation suggested a primary psychotic disorder; however, the presence of
seizures, cognitive dysfunction, and a concurrent ovarian teratoma prompted reconsideration of
the diagnosis. Cerebrospinal fluid analysis confirmed the presence of anti-NMDAR antibodies.
Treatment with first-line immunotherapy (corticosteroids), antiepileptic drugs (valproic acid),
and antipsychotics (aripiprazole) resulted in partial symptomatic improvement with persistent
residual deficits.
Clinical Significance: This case underscores the importance of maintaining high clinical
suspicion for autoimmune encephalitis in patients presenting with new-onset psychosis,
particularly when accompanied by seizures, cognitive dysfunction, or evidence of systemic
autoimmunity. Early diagnosis and prompt initiation of immunotherapy are crucial for optimal
neurological and psychiatric outcomes.